Efficacy of disitamab vedotin-containing therapy in metastatic colorectal cancer: A case report.

IF 2.6 Q3 ONCOLOGY

World journal of clinical oncology Pub Date : 2025-03-24 DOI:10.5306/wjco.v16.i3.99527

Hu-Cheng Yan, Yan Liu, You Feng, Jun-Ming Li, Lei-Ming Sheng, Xin Chen, Yu-Ping Xie, Na Li

{"title":"Efficacy of disitamab vedotin-containing therapy in metastatic colorectal cancer: A case report.","authors":"Hu-Cheng Yan, Yan Liu, You Feng, Jun-Ming Li, Lei-Ming Sheng, Xin Chen, Yu-Ping Xie, Na Li","doi":"10.5306/wjco.v16.i3.99527","DOIUrl":null,"url":null,"abstract":"Background: Colorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide. In cases of metastatic CRC (mCRC) that are resistant to conventional chemotherapy-based treatments, the efficacy of available therapeutic options is typically low. CRC exhibiting overexpression or amplification of the human epidermal growth factor receptor 2 (HER2) gene has shown responsiveness to HER2-targeted therapies.Case summary: We present the case of a 69-year-old woman diagnosed with mCRC with an NRAS p.G12V mutation and microsatellite stability, identified through tumor sequencing, along with HER2 overexpression detected by immunohistochemistry. She exhibited an excellent response to disitamab vedotin-containing therapy. To our knowledge, this is the first reported case of mCRC with HER2 overexpression and an NRAS p.G12V mutation achieving a remarkable clinical response to anti-HER2 therapy.Conclusion: Disitamab vedotin demonstrates promising anti-tumor effects in HER2-overexpressing mCRC, offering patients an additional treatment option.","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 3","pages":"99527"},"PeriodicalIF":2.6000,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11866092/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World journal of clinical oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5306/wjco.v16.i3.99527","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Colorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide. In cases of metastatic CRC (mCRC) that are resistant to conventional chemotherapy-based treatments, the efficacy of available therapeutic options is typically low. CRC exhibiting overexpression or amplification of the human epidermal growth factor receptor 2 (HER2) gene has shown responsiveness to HER2-targeted therapies.

Case summary: We present the case of a 69-year-old woman diagnosed with mCRC with an NRAS p.G12V mutation and microsatellite stability, identified through tumor sequencing, along with HER2 overexpression detected by immunohistochemistry. She exhibited an excellent response to disitamab vedotin-containing therapy. To our knowledge, this is the first reported case of mCRC with HER2 overexpression and an NRAS p.G12V mutation achieving a remarkable clinical response to anti-HER2 therapy.

Conclusion: Disitamab vedotin demonstrates promising anti-tumor effects in HER2-overexpressing mCRC, offering patients an additional treatment option.

查看原文本刊更多论文

含地西他单维多汀治疗转移性结直肠癌的疗效：1例报告。

背景：结直肠癌（CRC）是世界范围内癌症相关死亡的主要原因。在转移性结直肠癌（mCRC）的情况下，对传统的基于化疗的治疗有耐药性，可用的治疗方案的疗效通常很低。表现出人表皮生长因子受体2 （HER2）基因过表达或扩增的结直肠癌对HER2靶向治疗表现出反应性。病例总结：我们报告了一名69岁女性被诊断为mCRC的病例，通过肿瘤测序确定了NRAS p.G12V突变和微卫星稳定性，并通过免疫组织化学检测了HER2过表达。她对含地西他麦维多丁的治疗表现出极好的反应。据我们所知，这是第一例报道的HER2过表达和NRAS p.G12V突变对抗HER2治疗产生显著临床反应的mCRC病例。结论：地西他单维多汀在her2过表达的mCRC中显示出有希望的抗肿瘤作用，为患者提供了额外的治疗选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

World journal of clinical oncology ONCOLOGY-

自引率

0.00%

发文量

585

期刊介绍： The WJCO is a high-quality, peer reviewed, open-access journal. The primary task of WJCO is to rapidly publish high-quality original articles, reviews, editorials, and case reports in the field of oncology. In order to promote productive academic communication, the peer review process for the WJCO is transparent; to this end, all published manuscripts are accompanied by the anonymized reviewers’ comments as well as the authors’ responses. The primary aims of the WJCO are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in oncology. Scope: Art of Oncology, Biology of Neoplasia, Breast Cancer, Cancer Prevention and Control, Cancer-Related Complications, Diagnosis in Oncology, Gastrointestinal Cancer, Genetic Testing For Cancer, Gynecologic Cancer, Head and Neck Cancer, Hematologic Malignancy, Lung Cancer, Melanoma, Molecular Oncology, Neurooncology, Palliative and Supportive Care, Pediatric Oncology, Surgical Oncology, Translational Oncology, and Urologic Oncology.